Published in final edited form as:

Tetrahedron. 2010 July 1; 66(27-28): 4961–4964. doi:10.1016/j.tet.2010.04.110.

Monomers for preparation of amide linked RNA: Synthesis of C3'-homologated nucleoside amino acids from D-xylose

Paul TanuiMartin KullbergNi SongYashodhan ChivateEriks Rozners

Department of Chemistry, Binghamton University, State University of New York, Binghamton, New York 13902

Abstract

Amides as neutral and hydrophobic internucleoside linkages in RNA are highly interesting modifications for RNA interference. However, testing amides in siRNAs is hampered by the shortage of efficient methods to synthesize the monomeric building blocks, the nucleoside amino acid equivalents. This paper reports an efficient synthesis of protected ribonucleoside 5'-amino 3'-carboxylic acids from D-xylose in 14 steps 7% overall yield. The key features that ensure efficiency and ease of operations are chemoselective reduction of the ester and minimization of protecting group manipulation.

Keywords

RNA; Modified nucleoside; Amide internucleoside linkage; Carbohydrate synthesis; Selective reduction of ester

1. Introduction

The potential of RNA interference (RNAi) to become a new therapeutic strategy has revitalized the interest in chemical modifications of RNA. To be useful as therapeutic agents short interfering RNAs (siRNAs) need to be chemically modified to optimize their potency, enzymatic stability, cellular uptake, biodistribution, and pharmacokinetics.¹ We have been interested in hydrophobic non-ionic mimics of phosphate backbone, such as formacetals² and amides³ (Figure 1). Non-ionic phosphate mimics may offer several advantages for siRNAs: (1) the absence of natural phosphate will confer high nuclease resistance, (2) the reduction of charge may facilitate crossing of cellular membranes and (3) the increased hydrophobicity of siRNAs may improve their biodistribution and pharmacokinetics.

In previous studies we found that replacement of selected phosphates with amide linkages (Figure 1) did not change the overall conformation and UV melting temperature (thermal stability) of RNA double helix.³ The amide linkages appeared to be excellent mimics of phosphate backbone in RNA and were expected to be compatible with RNAi machinery. In

© 2010 Elsevier Ltd. All rights reserved.

Correspondence to: Eriks Rozners.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Supplementary Material

Supplementary data associated with this article can be found, in the online version, at ...

accord with such expectation, Iwase et al.⁴ recently reported that an siRNA having two amide linkages at the overhanging uridines retained high activity in RNAi assays. These results suggest a hypothesis that siRNAs may tolerate even more extensive amide modification, which may realize the potential advantages of the hydrophobic RNA modifications. The bottleneck of testing the above hypothesis is the shortage of efficient and large scale syntheses of enantiomerically pure C3'-homologated carboxylic acids **1** (Figure 1), the monomers for introduction of consecutive amide linkages in siRNAs.

In their study of amide modified siRNAs, Iwase et al.⁴ used uridine carboxylic acids, which were prepared from uridine following a procedure by Robins and co-workers.⁵ The problem with such an approach is that four independent synthetic routes must be pursued to prepare all four nucleoside carboxylic acids, which is time and resources consuming. Robins and co-workers have also developed synthesis of **1** starting from D-glucose or D-xylose.⁶ The sugar route diverges at the common intermediate **2** (Figure 1) on which the desired heterocycles can be installed in a straightforward manner. However, we found that Robin's route from sugars was complicated at the final steps by the need to cleave the ester (see **2**) and, consequently, laborious reintroduction of 2'-OH and heterocycle protecting groups, which being base labile, were lost during the ester cleavage.

Recently, we reported an asymmetric de novo synthesis of **1** starting from small molecules and proceeding through the common intermediate **3**.⁷ The final oxidation of alcohol led to straightforward and efficient preparation of carboxylic acids **1**. However, we encountered difficulties in scaling up the enantioselective reactions during the starting steps of de novo route. The de novo route started with a double asymmetric ene reaction that could be performed on a 4 g scale (13 mmol) of 1-(*tert*-butyldiphenylsiloxy)-3-pentene, but required an excess of 28 g (130 mmol) of (1*S*, 2*R*, 5*S*)-menthyl glyoxylate.

Preparation of pure menthyl glyoxylate⁸ involved column chromatography and vacuum distillation and was not practical on scales larger than 28 g. The double asymmetric reaction involving large excess of menthyl glyoxylate was necessary to insure good yields and high enantiomeric purity (>98:2) of the product and it appeared unlikely that this reaction could be scaled up to >50 mmol required to support our planned studies.

Herein we report optimization of our synthetic route⁷ by adopting the initial steps from the Robin's synthesis to prepare the key intermediate **3** starting from D-xylose.⁶ The key features that ensure efficiency of the new route are chemoselective reduction of the ester and minimization of protecting group manipulation.

2. Results and discussion

Our synthesis (Scheme 1) started with the C3'-homologated ribose derivatives **5** and **6**, which were prepared as described by Robins and co-workers.⁶ The plan was to reduce the ester before installation of the azide and then oxidize the alcohol after the nucleoside synthesis as was successfully done in our de novo route.⁷ In this way we would avoid the cleavage of ester under basic conditions after the nucleoside synthesis. Direct reduction of **5** would generate two primary alcohols, which would be difficult (if at all possible) to selectively functionalize. To avoid additional protecting groups we decided to use the mesyl

group (Ms, Scheme 1) as both differentiating functionality for the 5-OH in **5** and leaving group for later nucleophilic substitution with azide.⁸ Treatment of alcohol **5** with methanesulfonyl chloride, as described by Robins and co-workers, gave mesylate **6**.⁶

The challenge with such an approach was the selective reduction of the ester in the presence of potentially reactive mesyl group. Of several reducing agents tried (Table 1), the best results were obtained with DIBAL-H at 0 °C.¹⁰ Borane dimethyl sulfide complex¹¹ also performed well but required elevated temperature (60 °C) and longer reaction time. While LiAlH₄ and Ca(BH₄)₂ (formed in situ from NaBH₄ and CaCl₂ 12) gave good yields, LiBH₄ with catalytic amounts of 9BBN¹³ gave complex reaction mixture containing no target product.

Importantly, the mesylation and DIBAL-H reduction steps gave products in acceptable purity without the need for column chromatography. Treatment of mesylate **7** with lithium azide gave alcohol **8**, which was purified by silica gel column chromatography. Treatment of **8** with TBDPCL gave **9**, which was used in next step again without chromatographic purification.

The most challenging step in our synthesis was the removal of the 1,2-isopropylidene protecting group. Cleavage of 1,2-acetals in carbohydrates generally requires relatively harsh conditions. In our case, the TBDPS ether, which was relatively close on the same side of the tetrahydrofuran ring (see **9** in Scheme 1), further complicated the reaction. Typical protic acid hydrolysis procedures (Table 2) gave either no reaction (entry 1) or led to concurrent cleavage of the TBDPS group (entries 2–7).

Acceptable yield of **10** was achieved using BCl₃¹⁴ after recycling of the recovered starting material. Acylation with pyridine/acetic anhydride gave the glycosyl donor **3**, which serves as a common intermediate in synthesis of the modified nucleosides.

Final steps in preparation of all four ribonucleoside 5'-amino 3'-carboxylic acids from the common intermediate **3** have been previously reported by us.⁷ Following these procedures we used **3**, prepared from D-xylose, to synthesize uridine derivative **11**. The product obtained was identical to **11** previously synthesized via the de novo route.⁷ Following the reported procedures **11** was further converted to the uridine azido acid **1** (Scheme 2). Reduction of azide with hydrogen sulfide was immediately followed by protection of the amino group with methoxytrityl chloride to give the amino acid **13**, suitable for solid phase synthesis of oligoamides.

3. Conclusion

In summary, we have developed a new synthesis of uridine 5'-azido 3'-carboxylic acid **1** from D-xylose in 14 steps 7% overall yield. One step reduction followed by protection of amino group gave the target 5'-amino 3'-carboxyl uridine **13** in 67% yield. Although the yield of the new route is somewhat lower than that of our previous de novo synthesis (9 steps and 19% to **1**),⁷ the ability to produce enantiomerically pure material on larger scales is an important advantage for our current studies on solid phase synthesis of oligoamides. While the start of our de novo route was limited to ca 13 mmol scale in the first step, the new route could be easily started with 200 mmols (30 g) of D-xylose. We envision that the new route should allow future preparation of the target nucleoside 5'-azido 3'-carboxylic acids on a gram scale.

The route presents formal synthesis of all four ribonucleoside 5'-azido 3'-carboxylic acids (**1**) because it makes the common intermediate **3** described in our previous work.⁷ The key features that ensure efficiency and ease of operations are chemoselective reduction of the

ester, minimization of protecting group manipulation and minimization of silica gel column purification steps. The efficiency may be further increased by optimization of the removal of the 1,2-isopropylidene protecting group. The new route should facilitate synthesis and testing of amide-modified siRNAs, which have shown promising results in initial studies.⁴

4. Experimental section

4.1. 3-Deoxy-3-(2-hydroxyethyl)-1,2-O-isopropylidene-5-O-(methanesulfonyl)- α -D-ribofuranose (7)

DIBAL-H (46.5 mL, 45.6 mmol, 25% in hexanes) was added slowly to a solution of **6** (7.88 g, 23.2 mmol) in anhydrous CH_2Cl_2 (120 mL) at 0 °C. The solution was stirred at 0 °C for 1 h. The reaction was quenched by extracting with diluted HCl (0.2%, 150 mL), the organic layer was separated, filtered to remove solid particles and dried with anhydrous Na_2SO_4 . Evaporation gave the *title compound* **7** (6.43 g, 94 %) as a colorless oil, which could be used in next step without further purification. ^1H NMR (CDCl_3 , 360 MHz) δ 5.78 (d, J = 3.6 Hz, 1H), 4.69 (m, 1H), 4.44 and 4.26 (ABX, J = 2.2, 4.3, 11.5 Hz, 2H), 4.03 (m, 1H), 3.74 (m, 2H), 3.04 (s, 3H), 2.13 (m, 1H), 1.91 (sb, 1H), 1.86 (m, 1H), 1.63 (m, 1H), 1.47 (s, 3H), 1.30 (s, 3H). ^{13}C NMR (CDCl_3 , 90 MHz) δ 111.8, 104.9, 81.0, 79.2, 68.6, 60.6, 41.6, 37.6, 29.6, 27.5, 26.4. MS (ESI) Calcd for $2\times\text{C}_{11}\text{H}_{20}\text{O}_7\text{S}+\text{Na}$ 615.2; found 614.7.

4.2. 5-Azido-3,5-dideoxy-3-(2-hydroxyethyl)-1,2-O-isopropylidene- α -D-ribofuranose (8)

LiN_3 (4.48 g, 89.5 mmol) was added to a solution of **7** (5.30 g, 17.9 mmol) in anhydrous DMF (50 mL). The solution was heated to 60 °C and stirred at this temperature for 14 h. The solution was concentrated in vacuum, the residue was dissolved in ethyl acetate (40 mL) and washed with brine (30 mL) and water (3×30 mL), the organic layer was dried with Na_2SO_4 , filtered and evaporated in vacuum. The crude product was purified on silica gel column using hexane/ethyl acetate (4:1 v/v) to give the *title compound* (4.11 g, 94 %) as a colorless oil. ^1H NMR (CDCl_3 , 360 MHz) δ 5.81 (d, J = 3.1 Hz, 1H), 4.67 (m, 1H), 3.98 (m, 1H), 3.75 (m, 2H), 3.62 (dd, J = 3.0, 13.7 Hz, 1H), 3.23 (dd, J = 4.7, 13.7 Hz, 1H), 2.12 (m, 1H), 1.84 (m, 1H), 1.58 (m, 1H), 1.49 (s, 3H), 1.32 (s, 3H). ^{13}C NMR (CDCl_3 , 90 MHz) δ 111.7, 104.8, 81.2, 80.4, 60.9, 51.5, 42.5, 27.6, 26.6, 26.3.

4.3. 5-Azido-3,5-dideoxy-3-[2-(tert-butyldiphenylsilyloxy)-ethyl]-1,2-O-isopropylidene- α -D-ribofuranose (9)

To a solution of **8** (2.41 g, 9.9 mmol) in imidazole (1.47 g, 21.6 mmol) in anhydrous DMF (20 mL), was added *tert*-butyldiphenylsilyl chloride (3.1 mL, 11.8 mmol). The solution was stirred at room temperature over night. The reaction was then quenched with water, evaporated in vacuum and the residue was dissolved in EtOAc (20 mL) and washed once with brine (15 mL) then with water (3×15 mL). The organic layer was dried with Na_2SO_4 , filtered and evaporated in vacuum to give the *title compound* **9** (3.75 g, 79%) as a crude colorless oil whose purity was acceptable for the next step. ^1H NMR (CDCl_3 , 360 MHz) δ 7.71 (m, 4H), 7.44 (m, 6H), 5.77 (d, J = 3.4 Hz, 1H), 4.42 (m, 1H), 3.98 (m, 1H), 3.82 (m, 2H), 3.61 (dd, J = 3.0, 13.7 Hz, 1H), 3.20 (dd, J = 4.8, 13.2 Hz, 1H), 2.17 (m, 1H), 1.84 (m, 1H), 1.55 (m, 1H), 1.49 (s, 3H), 1.29 (s, 3H), 1.11 (s, 9H). ^{13}C NMR (CDCl_3 , 90 MHz) δ 135.6, 129.7, 127.6, 111.6, 104.9, 80.9, 61.9, 51.6, 42.3, 27.6, 26.8, 19.1. MS (ESI) Calcd for $\text{C}_{26}\text{H}_{35}\text{N}_3\text{NaO}_4\text{Si}$ 504.2; found 504.2.

4.4. 5-Azido-3,5-dideoxy-3-[2-(tert-butyldiphenylsilyloxy)-ethyl]- α -D-ribofuranose (10)

A solution of **9** (1.505 g, 3.12 mmol) in anhydrous CH_2Cl_2 (40 mL) was cooled to 0 °C and then treated with BCl_3 (3.12 mL, 3.12 mmol, 1M solution in hexanes) for 30 minutes. The reaction was quenched with saturated NaHCO_3 (50 mL) and brought to room temperature, the aqueous layer was extracted with CH_2Cl_2 (3×50 mL). The organic layers were pooled

together, dried with Na₂SO₄, filtered and evaporated in vacuum. The residue was purified on silica gel column using hexane/ethyl acetate (4:1 v/v) to give the *title compound* **10** (0.309g, 0.718 mmol, 23%) as a colorless oil. After chromatography 0.624g, 40% of **9** was recovered bringing the yield of **10** to 38% based on the recovered starting material. The spectroscopic data are for mixture of α and β diastereomers. ¹H NMR (CDCl₃, 360 MHz) δ 7.70-7.64 (m, 4H), 7.47-7.39 (m, 6H), 5.48 and 5.38 (d, J = 3.4 Hz, 1H), 4.31-4.25 (m, 1H), 4.10-4.04 (m, 1H), 3.83-3.65 (m, 2H), 3.57-3.48 (m, 1H), 3.31 (dd, J = 5.5, 13.2 Hz), 3.12 and 3.03 (dd, J = 4.3, 13.2 Hz), 2.40-2.30 and 2.23-2.14 (m, 1H), 1.97-1.85 (m, 1H), 1.68-1.50 (m, 1H), 1.07 (s, 9H). ¹³C NMR (CDCl₃, 90 MHz) δ 135.5, 132.5, 130.0, 127.8, 102.8, 98.2, 82.9, 80.0, 71.8, 63.3, 54.2, 52.4, 42.8, 28.0, 26.7, 18.9.

4.5. 5-Azido-3,5-dideoxy-3-[2-(tert-butyldiphenylsilyloxy)-ethyl]-1,2-O-diacetyl- α -D-ribofuranose (**3**)

Compound **10** (0.8 g, 1.81 mmol) was dissolved in pyridine/acetic anhydride (6 mL, 1:1 v/v) and stirred at room temperature for 12 hours. The solution was concentrated in vacuum, the residue was dissolved in EtOAc (50 mL) and washed with saturated aqueous NaHCO₃ (3 $\times$ 50 mL). The organic layer was dried with anhydrous Na₂SO₄, filtered and evaporated under vacuum to give the *title compound* **3** (0.809g, 1.54 mmol, 85%) as colorless oil of purity acceptable for the next step. The spectroscopic data are for mixture of α and β diastereomers. ¹H NMR (CDCl₃, 360 MHz) δ 7.69-7.61 (m, 4H), 7.46-7.36 (m, 6H), 6.38 and 6.08 (d, J = 3.1 Hz, 1H), 5.24-5.16 (m, 1H), 4.24-4.18 and 4.13-4.08 (m, 1H), 3.74-3.58 (m, 3H), 3.27-3.23 and 3.18-3.14 (dd, J = 4.3, 13.7 Hz, 1H), 2.77-2.68 and 2.55-2.46 (m, 1H), 2.09 (s, 3H), 2.03 (s, 3H), 1.81-1.50 (m, 2H), 1.06 (s, 9H). ¹³C NMR (CDCl₃, 90 MHz) δ 135.5, 129.7, 127.7, 98.7, 83.8, 82.7, 61.7, 38.0, 29.7, 27.4, 26.8, 20.6.

4.6. 2'-O-Acetyl-5'-azido-3'-[2-(tert-butyldiphenylsiloxy) ethyl]-3',5'-dideoxyuridine (**11**)

The *title compound* **11** was prepared from **3** (0.222 g, 0.412 mmol) as previously described by us⁷ in 95% yield (0.226 g). The ¹H and ¹³C NMR matched the reported data.⁷ Elemental analysis (C₂₉H₃₅N₅O₆Si): calculated C, 60.29; H, 6.11; N, 12.12; found C, 60.44; H, 6.17; N, 11.78.

4.7. 2'-O-Acetyl-3',5'-dideoxy-3'-carboxymethyl-5'-(monomethoxytrityl)amino-uridine triethylammonium salt (**13**)

Hydrogen sulfide was passed through a solution of **1** (275 mg, 0.78 mmol) in pyridine/water (25 mL, 4:1 v/v) for 1 h at room temperature. The solution was stirred over night and evaporated in vacuum. The residue was dissolved in water (50 mL) and washed with CH₂Cl₂ (4 $\times$ 50 mL). The organic layers were discarded and the water phase was evaporated to give amine **12** (~230 mg, ~0.70 mmol, ~90%), which was used in the next step without further purification. Amine **12** was dissolved in anhydrous pyridine (10 mL) and 4-methoxytrityl chloride (1.08g, 3.5 mmol) was added. The solution was stirred at room temperature over night. The reaction was quenched with saturated aqueous triethylammonium bicarbonate (1 mL) and evaporated in vacuum. The residue was dissolved in CH₂Cl₂ (50 mL) and extracted with saturated aqueous NaHCO₃ (3 $\times$ 50 mL). The organic phase was dried with Na₂SO₄, filtered and concentrated in vacuum. The residue was purified on silica gel column eluting with a stepwise gradient of MeOH (0–10%) in CH₂Cl₂ containing 100 ppm of triethylamine to give the *title compound* **13** (362 mg, 0.52 mmol, 67 % for two steps). ¹H NMR (CDCl₃, 300 MHz) δ 7.65 (d, J = 8.6 Hz, 1H), 7.29 (m, 12H), 6.80 (d, J = 9.0 Hz, 2H), 5.81 (s, 1H), 5.60 (d, J = 8.1 Hz, 1H), 5.46 (d, J = 5.7 Hz, 1H), 4.04 (m, 1H), 3.76 (s, 3H), 2.95 (q, J = 7.1 Hz, 6H), 2.72 (m, 2H), 2.26 (m, 3H), 2.06 (s, 3H), 1.17 (t, J = 7.14 Hz, 9H). ¹³C NMR (CDCl₃, 72 MHz) δ 175.7, 169.6, 163.7, 158.2, 150.7, 150.1, 146.2, 146.1, 140.4, 137.9, 130.1, 128.7, 128.1, 126.6, 113.5, 102.5, 90.3,

84.3, 78.4, 70.5, 55.4, 45.4, 45.2, 39.6, 31.2, 29.9, 20.8, 8.6. HRMS (ESI) Calcd for $C_{33}H_{33}N_3NaO_8$, 622.2165; Found, 622.2157.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Binghamton University and NIH (R01 GM071461) for support of this research.

References and notes

1. Watts JK, Deleavey GF, Damha MJ. Drug Discovery Today 2008;13:842–855. [PubMed: 18614389] Corey DR. J. Clin. Invest 2007;117:3615–3622. [PubMed: 18060019] Rozners E. Curr. Org. Chem 2006;10:675–692. Manoharan M. Curr. Opin. Chem. Biol 2004;8:570–579. [PubMed: 15556399]
2. Kolarovic A, Schweizer E, Greene E, Gironda M, Pallan PS, Egli M, Rozners E. J. Am. Chem. Soc 2009;131:14932–14937. [PubMed: 19824732] Rozners E, Katkevica D, Strömberg R. ChemBioChem 2007;8:537–545. [PubMed: 17300110] Rozners E, Strömberg R. J. Org. Chem 1997;62:1846–1850.
3. Rozners E, Katkevica D, Bizdena E, Strömberg R. J. Am. Chem. Soc 2003;125:12125–12136. [PubMed: 14518999]
4. Iwase R, Toyama T, Nishimori K. Nucleosides, Nucleotides & Nucleic Acids 2007;26:1451–1454. Iwase R, Miyao H, Toyama T, Nishimori K. Nucleic Acids Symposium Series 2006:175–176. [PubMed: 17150874]
5. Peterson MA, Nilsson BL, Sarker S, Doboszewski B, Zhang W, Robins MJ. J. Org. Chem 1999;64:8183–8192. [PubMed: 11674735]
6. Robins MJ, Doboszewski B, Timoshchuk VA, Peterson MA. J. Org. Chem 2000;65:2939–2945. [PubMed: 10814181]
7. Rozners E, Liu Y. J. Org. Chem 2005;70:9841–9848. [PubMed: 16292814] Rozners E, Liu Y. Org. Lett 2003;5:181–184. [PubMed: 12529135]
8. Whitesell JK, Lawrence RM, Chen H-H. J. Org. Chem 1986;51:4779–4784.
9. Matin MM. J. Appl. Sci. Res 2008;4:1478–1482.
10. Yoon NM, Gyoung YS. J. Org. Chem 1985;50:2443–2450.
11. Brown HC, Choi YM, Narasimhan S. J. Org. Chem 1982;47:3153–3163.
12. Hou D, Reibenspies JH, Burgess K. J. Org. Chem 2001;66:206–215. [PubMed: 11429902]
13. Piers E, Chong JM. J. Org. Chem 1982;47:1604–1606.
14. Nicolaou KC, Daines RA, Uenishi J, Li WS, Papahatjis DP, Chakraborty TK. J. Am. Chem. Soc 1988;110:4672–4685.

Figure 1.
Structure and retrosynthetic analysis of amide linked RNA.

Scheme 1.
Synthesis of C3'-homologated uridine.

Scheme 2.
Synthesis of uridine 5'-amino 3'-carboxylic acid.

Table 1

Results of selective reduction of ester **6**.

	Reagent	Solvent	Temp. (°C)	Time (h)	Yield (%)
1	DIBAL-H	CH ₂ Cl ₂ , hexane	0	1	94
2	BH ₃ ·Me ₂ S	THF	60	2	93
3	LiAlH ₄	Dimethoxyethane	0	2	78
4	NaBH ₄ , CaCl ₂	THF	25	24	74
5	LiBH ₄ -9BBN	THF, toluene	100	24	0

Table 2Results of cleavage of isopropylidene in **9**.

	Reagent	Temp (°C)	Time (h)	Yield (%)
1	Amberlyst-15/MeOH	25	overnight	NR ^a
2	THF/TFA/H ₂ O (5:4:1)	25	overnight	0 ^b
3	80% Acetic acid	80	overnight	0 ^b
4	5% methanesulfonic acid/MeOH	25	overnight	0 ^b
5	0.3% H ₂ SO ₄ /MeOH	25	overnight	0 ^b
6	0.5M HCl/THF	50	overnight	0 ^b
7	H ₂ SO ₄ /AcOAc/AcOH (1:2:60)	25	overnight	29% ^c
8	BBr ₃ in hexanes/CH ₂ Cl ₂ (3:40)	−78 to 0	0.5	0 ^c
9	BCl ₃ in hexanes/CH ₂ Cl ₂ (3:40)	0	0.5	38% ^d

^a No reaction,^b Cleavage of TBDPS,^c Decomposition to polar by-products,^d Based on recovered starting material.